Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), also known as Alpha Cognition (ACI), a biopharmaceutical company focused on developing novel treatments for severe neurodegenerative disorders, is excited to announce the submission of a new composition-of-matter patent. This patent aims to provide extensive protection for its lead asset, ALPHA-1062, which is currently under FDA review for the treatment of mild-to-moderate Alzheimer’s Disease.

The patent application has been filed with the USPTO and may potentially extend to cover global protection. If approved, it will safeguard the composition-of-matter of an oral formulation of ALPHA-1062. The decision to file the patent application was based on significant findings from the company's clinical trials, highlighting the uniqueness of ALPHA-1062. Approval of the patent would ensure protection for ALPHA-1062 until 2044, complementing existing patent coverage that extends until 2042.

“The filing of this patent application is a crucial step in our strategy to establish robust protection for ALPHA-1062, a promising treatment option for individuals with mild-to-moderate Alzheimer’s Disease. Securing this patent will provide protection until 2044 in the United States, enabling our team to fully capitalize on the potential benefits that ALPHA-1062 offers to patients and healthcare providers.”

Source: businesswire.com